雾化黏菌素的应用进展  

Application Progress of Aerosolized Colistin

作　　者：李立[1] 叶璟[1] 胡蕾[1] 谈林华[1] LI Li;YE Jing;HU Lei;TAN Linhua(Department of Surgical Intensive Care Unit,Children′s Hospital,Zhejiang University School of Medicine/National Clinical Research Center for Child Health,Hangzhou 310052,China)

机构地区：[1]浙江大学医学院附属儿童医院外科重症监护室国家儿童健康与疾病临床医学研究中心,杭州310052

出　　处：《医学综述》2021年第24期4898-4903,共6页Medical Recapitulate

基　　金：国家中心自主设计项目全国多中心临床研究项目(G20B0009)。

摘　　要：近年来由多重耐药革兰阴性细菌引起的医院获得性肺炎(HAP)的发病率显著升高,而抗生素治疗的选择越来越有限,严重威胁人类健康。黏菌素对大多数革兰阴性菌具有杀灭作用,是目前治疗由多重耐药革兰阴性细菌引起的HAP的重要手段。随着黏菌素在囊性纤维化和支气管扩张中作用的明确,雾化黏菌素因具有优化治疗的潜力而引起高度关注,但雾化黏菌素给药策略的实施有赖于对其药动学和不良反应的进一步认识。未来雾化黏菌素将成临床医师治疗HAP的重要选择。The global rise in hospital acquired pneumonia(HAP)caused by multidrug-resistant Gram-negative bacteria and the increasingly limited antibiotic treatment options are growing threats to people′s health.Colistin is bactericidal against most aerobic Gram-negative bacteria,and is an important treatment for hospital-acquired pneumonia caused by multidrug-resistant Gram-negative bacteria.With an established role in cystic fibrosis and bronchiectasis,the potential of aerosolized colistin to optimize therapy is considered of high interest,although the implementation of aerosolized colistin administration strategy depends on the further understanding of its pharmacokinetics and adverse effects.Aerosolized colistin will become an important choice for the clinicians in the treatment of HAP.

关 键 词：黏菌素 雾化黏菌素 多重耐药 药动学 

分 类 号：R978.16[医药卫生—药品]